Source link : https://www.newshealth.biz/health-news/does-acalabrutinib-fit-into-frontline-mcl-therapy/
For younger, fit patients with mantle cell lymphoma (MCL), adding the Bruton’s tyrosine kinase (BTK) inhibitor acalabrutinib to standard induction therapy with bendamustine/rituximab followed by cytarabine/rituximab adds toxicity without improving efficacy, results of the phase 2 ECOG-ACRIN EA4181 trial indicate. However, treating patients with bendamustine/rituximab plus acalabrutinib might be preferred to either option with cytarabine. […]
Author : News Health
Publish date : 2024-12-10 06:59:22
Copyright for syndicated content belongs to the linked Source.